AACR Project GENIE: 100,000 Cases and Beyond
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international pan-cancer registry with the goal to inform cancer research and clinical care worldwide. Founded in late 2015, the milestone GENIE 9.1-public release contains data from >110,000 tumors from >100,000 people treated at 19 cancer centers from the United States, Canada, the United Kingdom, France, the Netherlands, and Spain. Here, we demonstrate the use of these real-world data, harmonized through a centralized data resource, to accurately predict enrollment on genome-guided trials, discover driver alterations in rare tumors, and identify cancer types without actionable mutations that could benefit from comprehensive genomic analysis. The extensible data infrastructure and governance framework support additional deep patient phenotyping through biopharmaceutical collaborations and expansion to include new data types such as cell-free DNA sequencing. AACR Project GENIE continues to serve a global precision medicine knowledge base of increasing impact to inform clinical decision-making and bring together cancer researchers internationally. Significance: AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged as a powerful resource to evaluate genome-guided clinical trial design, uncover drivers of cancer subtypes, and inform real-world use of genomic data. This article is highlighted in the In This Issue feature, p. 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationCOSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“The mechanisms underlying therapeutic resistance are complex and can include innate insensitivity, gain of secondary mutations in the drug target, and other adaptive responses (29).”
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“Following the approval of the alpha-selective PI3K inhibitor alpelisib for the treatment of PIK3CA -mutated, hormone receptor–positive breast cancer in 2019, these patients now have a level 1 therapy option (16).”
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“…for KRAS G12C -mutant non–small cell lung carcinoma (17), PARP inhibitors for prostate cancer with homologous recombination repair gene mutations (18, 19), IDH and FLT3 inhibitors for leukemia (20–23), FGFR inhibitors for bladder and hepatobiliary cancers (24, 25), MET inhibitors for NSCLC (26),…”
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · cited 1×
“Other recent FDA approvals include sotorasib for KRAS G12C -mutant non–small cell lung carcinoma (17), PARP inhibitors for prostate cancer with homologous recombination repair gene mutations (18, 19), IDH and FLT3 inhibitors for leukemia (20–23), FGFR inhibitors for bladder and hepatobiliary…”
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“…cancer with homologous recombination repair gene mutations (18, 19), IDH and FLT3 inhibitors for leukemia (20–23), FGFR inhibitors for bladder and hepatobiliary cancers (24, 25), MET inhibitors for NSCLC (26), and BRAF inhibitors for colorectal, thyroid, and histiocytic neoplasms (13, 27, 28).”
Cited by
COSMIC: a curated database of somatic variants and clinical data for cancer
Sondka, Z., Dhir, N. B., Carvalho-Silva, D., Jupe, S., Madhumita, McLaren, K., Starkey, M., Ward, S., Wilding, J., Ahmed, M., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad986 · Cited by 533
Trends in the approval of cancer therapies by the FDA in the twenty-first century
Scott, E. C., Baines, A. C., Gong, Y., Moore, R., Pamuk, G. E., Saber, H., Subedee, A., Thompson, M. D., Xiao, W., Pazdur, R., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00723-4 · Cited by 284
Harnessing Real-World Evidence to Advance Cancer Research
Tang, M., Pearson, S.-A., Simes, R. J., & Chua, B. H. (2023) · Current Oncology · doi:10.3390/curroncol30020143 · Cited by 88
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Hamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01781-y · Cited by 8
Metadata
- Authors
- Pugh, T. J., Bell, J. L., Bruce, J. P., Doherty, G. J., Galvin, M., Green, M. F., Hunter-Zinck, H., Kumari, P., Lenoue-Newton, M. L., Li, M. M., Lindsay, J., Mazor, T., Ovalle, A., Sammut, S.-J., Schultz, N., Yu, T. V., Sweeney, S. M., Bernard, B., & for the AACR Project GENIE Consortium, G. A. A. W. G.
- Venue
- Cancer Discovery
- Published
- 2022-07-12
- Volume
- 12
- Issue
- 9
- Pages
- 2044-2057
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4285077014
- Cited by
- 106
- References
- 15
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AACR Project GENIE: 100,000 Cases and Beyond. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1547
- The paper
- Pugh, T. J., Bell, J. L., Bruce, J. P., Doherty, G. J., Galvin, M., Green, M. F., Hunter-Zinck, H., Kumari, P., Lenoue-Newton, M. L., Li, M. M., Lindsay, J., Mazor, T., Ovalle, A., Sammut, S.-J., Schultz, N., Yu, T. V., Sweeney, S. M., Bernard, B., & for the AACR Project GENIE Consortium, G. A. A. W. G. (2022). AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.